Industry Overview

US DNA vaccine market was valued at $ 409.41 million in 2025 and is projected to reach $654.05 million by 2035, growing at a CAGR of 4.9% during the forecast period (2026–2035). The market is growing due to the rising demand for targeted immunization approaches in both human and animal health, particularly across oncology and infectious disease applications. DNA vaccines offer advantages such as rapid design, manufacturing flexibility, and improved stability compared to conventional vaccine platforms, which support their adoption in emerging and recurrent disease scenarios. In parallel, advancements in plasmid DNA vaccine technology and plasmid DNA delivery technology have enhanced transfection efficiency and immune response strength, addressing earlier limitations related to immunogenicity. Increasing research investments and clinical pipeline expansion across human and veterinary segments are further strengthening product development activity.

Market Dynamics

Expansion of Clinical Pipeline Targeting Oncology Applications

The US DNA vaccine market is witnessing increasing clinical activity in oncology, driven by the need for antigen-specific and personalized immunotherapy approaches. DNA vaccine platforms enable the encoding of tumor-associated antigens, supporting targeted immune activation against cancer cells. Ongoing clinical programs in solid tumors and hematological malignancies are strengthening the human DNA vaccine segment. The adaptability of plasmid constructs allows faster modification to address multiple cancer indications within a single development framework. This sustained pipeline expansion in oncology is reinforcing long-term commercial potential within the human DNA vaccine category.

Advancements in Plasmid DNA Delivery Technology Enhancing Immunogenicity

Technological progress in plasmid DNA delivery systems is emerging as a critical trend shaping the US DNA vaccine market. Innovations such as electroporation-based devices and optimized vector designs are improving cellular uptake and antigen expression levels. These improvements are addressing historical challenges related to low immune response in early-generation DNA vaccines. Enhanced delivery efficiency is accelerating clinical validation across both infectious disease and oncology applications. As delivery performance becomes more reliable, adoption across animal and human DNA vaccine segments is expected to strengthen, supporting overall market expansion.

Market Segmentation

• Based on the type, the market is segmented into animal DNA vaccine, and human DNA vaccine.
• Based on the technology, the market is segmented into plasmid DNA vaccines technology, and plasmid DNA delivery technology.
• Based on the application, the market is segmented into oncology, infectious diseases, and others.

Human DNA Vaccine Segment Driven by Expanding Clinical Development

The human DNA vaccine segment represents a leading sub-segment within the US DNA Vaccine market, primarily driven by increasing clinical development across infectious diseases and oncology indications. Growing demand for rapid vaccine design platforms has strengthened interest in plasmid-based constructs that can be adapted to emerging pathogens. In oncology, DNA vaccines encoding tumor-specific antigens are gaining traction as adjunct immunotherapies, expanding their therapeutic relevance. Continued regulatory engagement and structured clinical trial progression are improving the pathway toward commercialization. These factors collectively position the human segment as a central contributor to overall market revenue growth.

Plasmid DNA Delivery Technology Segment Supported by Improved Transfection Efficiency

Plasmid DNA delivery technology is a critical growth sub-segment within the US DNA Vaccine market, supported by advancements that enhance cellular uptake and antigen expression. Improved delivery approaches, including device-assisted administration methods, are addressing historical limitations related to low immunogenicity. Enhanced transfection efficiency directly influences clinical performance outcomes, thereby strengthening confidence in DNA vaccine platforms. Technology optimization is also enabling broader applicability across both animal and human vaccine categories. As delivery reliability improves, this segment is reinforcing its strategic importance in driving adoption across multiple applications within the market.

Market Players Outlook

The major companies operating in the US DNA vaccine market include Dynavax Technologies Corp., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Vaxart, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In November 2025, INOVIO completed the rolling submission of its Biologics License Application (BLA) for INO-3107, a DNA immunotherapy for treating recurrent respiratory papillomatosis (RRP) in adults. If approved, INO-3107 would be INOVIO's first commercial product and the first DNA medicine available in the US.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US DNA vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.